teaser
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Grifols has received approval from the FDA to market Alphanate (antihaemophilic factor/von Willebrand factor complex [human]) for the treatment of congenital von Willebrand disease (VWD) in connection with surgery or other invasive procedures.
The drug is indicated for the prevention and control of bleeding in patients with factor VIII deficiency. It is also indicted for surgical and/or invasive procedures in patients with VWD, except type 3 patients undergoing major surgery, in whom desmopressin is either ineffective or contraindicated.
